2013-09-02 16:46:02 -
Six and 12-Month Data from Largest Real-World Patient Population
Consistent with Symplicity Randomized Clinical Trial
MINNEAPOLIS and AMSTERDAM - September 2, 2013 - Medtronic, Inc. (NYSE: MDT),
announced today at the European Society of Cardiology (ESC) Congress, new data
from the Global SYMPLICITY Registry that continue to affirm the strong safety
profile of the Symplicity(TM) renal denervation system in a real-world patient
population. Among the 1,158 patients analyzed in the registry with follow-up
information available for this analysis, major complications or serious adverse
events related to delivery of radio frequency (RF) energy to the renal artery
were rare, including one procedural dissection (0.09 percent) and one re-
intervention at 6 months (0.09 percent).
The primary goal of the
Global SYMPLICITY Registry is to confirm procedural
safety with the Symplicity system. Available data for the secondary efficacy
analysis showed significant and sustained blood pressure reductions after renal
denervation with the Symplicity system at all time points up to 12 months in
both in-office and ambulatory blood pressure measurement, compared to baseline.
The Symplicity renal denervation system is available for investigational use
only in the United States.
"It is encouraging that preliminary data with this sizeable patient cohort in a
real-world setting continue to demonstrate a strong safety profile and
significant clinical efficacy for renal denervation with the Symplicity system,
similar to what we've been seeing in the randomized, controlled clinical trial,
Symplicity HTN-2," said Michael Böhm, MD, PhD, Chairman, Department of Internal
Medicine, University of Saarland, Homburg/Saar, Germany and Global SYMPLICITY
Data presented by Prof. Böhm during an oral session at ESC 2013 in Amsterdam on
Tuesday, September 2, 2013 reported patients with systolic blood pressure of
>=180 mm Hg at baseline (n=51) had an average in-office blood pressure reduction
of -29/-17 mm Hg from baseline at six months [p<0.001] and -37/-23mm Hg from
baseline at 12 months (n=9) [p=0.001 SBP/p=0.0005 DBP]. Patients with similar
characteristics to the Symplicity HTN-2 trial, with a systolic blood pressure
of ³160 mm Hg (or >=150 mm Hg in patients with diabetes) had an average in-
office blood pressure reduction of -19/-8 mm Hg from baseline at six months
(n=313) [p<0.001] and -22/-11 mm Hg from baseline at 12 months (n=79) [p<0.001].
Average reductions in available ambulatory blood pressure measurements were
-10/-5mm Hg from baseline to six months (n=132) [p<0.0001].
The Global SYMPLICITY Registry is a multi-center, prospective, observational
registry designed to collect comprehensive data evaluating procedural and long-
term safety of the Symplicity system, clinical efficacy for both in-office and
ambulatory blood pressure measurement, and long-term cardiovascular outcomes
from hypertension such as stroke, myocardial infarction, heart failure and
cardiovascular death. More than two thirds (66%) of registry patients treated to
date fall within current ESC consensus paper recommendations for catheter-based
renal denervation, including a systolic blood pressure of >= 160 mm Hg (>= 150
mmHg Diabetes II) and were taking at least three classes of anti-hypertensive
medications, including diuretic, prior to treatment with renal denervation.(1)
"We are pleased that enrollment and analysis of the registry continues to meet
our goal of establishing procedural safety and efficacy of the Symplicity
system, which we expect will ultimately help reduce the risk of cardiovascular
events associated with treatment-resistant hypertension such as stroke and
ischemic heart disease," said Dr. Bohm.
As the largest renal denervation registry in the world to date and the first-of-
its-kind to evaluate this novel treatment in a real-world, uncontrolled
population, The Global SYMPLICITY Registry will enroll more than 5,000 patients
in a minimum of 200 centers with planned follow-up to five years. The registry
also will gather data for other diseases characterized by elevated sympathetic
drive, such as diabetes mellitus type 2, heart failure and chronic kidney
With the continued success of the Global SYMPLICITY Registry, Medtronic
strengthens its position as the global leader in the research and development of
renal denervation therapies. Ultimately, Medtronic's global Symplicity clinical
program will involve more than 8,000 patients worldwide.
About the Symplicity Clinical Trial Program
Medtronic continues to lead the advancement of research and development in renal
denervation worldwide with more clinical studies ongoing than any other
manufacturer. Medtronic's rigorous clinical evaluation program of the Symplicity
renal denervation system involves more than 8,000 patients worldwide, including
the U.S., Europe, and Japan, with more than 1,200 of these patients
participating in randomized clinical trials.
* Symplicity HTN-1: A series of pilot studies at 19 centers in Australia,
Europe and the United States with 153 patients with systolic blood pressure
>=160 mm Hg enrolled. Symplicity HTN-1, the longest running clinical trial
investigating the safety and efficacy of renal denervation.
* Symplicity HTN-2: A randomized, controlled clinical trial of 106 patients
at 24 centers in Europe, Australia and New Zealand to investigate renal
denervation in patients with treatment-resistant hypertension randomly
allocated in a one-to-one ratio to undergo renal denervation with previous
treatment or to maintain previous treatment alone.
* SYMPLICITY HTN-3: Pivotal U.S. clinical trial of the Symplicity renal
denervation system for uncontrolled hypertension completed enrollment of
535 patients across nearly 90 U.S. medical centers in May 2013. The results
are expected to be available during the first half of 2014.
* SYMPLICITY HTN-4: First randomized, controlled trial to investigate renal
denervation for moderate uncontrolled hypertension in U.S. patients with
systolic blood pressure greater than or equal to 140 and less than 160 mm
Hg. Enrollment is expected to begin in fall 2013.
* Global SYMPLICITY Registry: Prospective, multi-center, open-label registry
of 5,000 patients in 200+ centers, designed to document the long-term safety
and effectiveness of renal denervation in real-world patient populations, as
well as gather data for other diseases characterized by elevated sympathetic
* SYMPLICITY-HF: Clinical study designed to evaluate the safety and
physiologic response to renal denervation with the Symplicity system in
patients with chronic heart failure and renal impairment. The study will
enroll approximately 40 adult subjects with chronic heart failure and renal
impairment in Europe and Australia.
* SYMPLICITY Spyral(TM) Catheter Feasibility Study: Prospective, single-arm,
non-randomized clinical study, which completed enrollment of 50 patients in
Australia and New Zealand designed to evaluate acute procedure safety and
change in office blood pressure from baseline at six months.
* SYMPLICITY HTN-Japan: Open-label study being conducted in approximately 100
patients across 11 centers in Japan, designed to randomize subjects 1:1 to
renal denervation versus no denervation with both groups receiving maximal
tolerated doses of antihypertensive medications.
About the Symplicity(TM) Renal Denervation System
The Symplicity renal denervation system is backed by over five years of clinical
experience in more than 5,000 patients with uncontrolled hypertension and is
available in more than 80 countries throughout the world. The Symplicity system
is a minimally invasive, device-based treatment option to those suffering with
uncontrolled hypertension that disrupts the output of hyperactive sympathetic
nerves within the renal artery wall, known to be central to the body's ability
to regulate blood pressure. It consists of a flexible catheter and proprietary
generator with which algorithms were carefully and specifically developed
through years of clinical experience to enhance the safety and effectiveness of
the renal denervation procedure. The Symplicity system received CE (Conformité
Européene) Mark in 2008.
In collaboration with leading clinicians, researchers and scientists worldwide,
Medtronic offers the broadest range of innovative medical technology for the
interventional and surgical treatment of cardiovascular disease and cardiac
Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global
leader in medical technology -- alleviating pain, restoring health and extending
life for millions of people around the world.
Any forward-looking statements are subject to risks and uncertainties such as
those described in Medtronic's periodic reports on file with the Securities and
Exchange Commission. Actual results may differ materially from anticipated
- end -
Symplicity is a trademark of Medtronic Inc. and is registered in one or more
countries of the world.
(1 )Mahfoud F et al. Expert consensus document from the European Society of
Cardiology on catheter-based renal denervation, Eur Heart J April 2013
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Medtronic, Inc. via Thomson Reuters ONE